Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for genetic clues to second breast cancer risk

NCT ID NCT00903591

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some women with breast cancer in one breast later develop cancer in the other breast. Researchers are comparing women with cancer in both breasts to those with cancer in only one breast. They are studying how genes, past radiation treatment, and lifestyle choices may increase the risk. The goal is to find better ways to detect, treat, and prevent breast cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,699 people

The number who actually took part.

Started

May 2009

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All of the WECARE:GWA Study participants (new cases and individually matched controls) will be identified, recruited, and interviewed by investigative teams in the five population-based cancer registries (NCC, OCR, FHCRC, Iowa, and DCS).

Ages

18 to 54 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligibility for Cases: All women who meet the following eligibility requirements will be recruited as cases for the WECARE:GWA Study if they are not already cases (or refusers) from the parent WECARE Study: * Diagnosed since 1/1/1990 with a histologically confirmed first primary breast cancer (only invasive stage 1 or 2) while residing in one of the study enrollment site (cancer registry); * Diagnosed since 1/1/1992 with CBC (invasive only any stage) while residing in the same enrollment site (cancer registry); * Two years or longer time interval between first and second primaries; Between the ages of 18 and 54 at the time of diagnosis of the first primary; * Alive at time of contact; and * No history of previous or intervening cancer diagnosis, except cervical cancer in situ (CIS) or non-melanoma skin cancer. * Without bilateral mastectomy or prophylactic mastectomy of the contralateral breast following diagnosis of their first primary. Eligibility for Controls: Women who meet all of the following requirements will be eligible as controls. One matched control will be recruited for each participating case: * Diagnosed since 1/1/1990 with their first primary breast cancer (only invasive stage 1 or 2) while residing in one of the study enrollment site (i.e., cancer registry); * Between the ages of 18 and 54 at the time of diagnosis of the first primary; * Residing in the same study enrollment site (cancer registry) as when they were diagnosed with their breast cancer; * Alive at time of contact; * Never diagnosed (at reference date (date of first diagnosis plus "at risk interval" of matched case)) as having had CBC or any other cancer diagnosis other than the original breast cancer; with the exception of CIS or non-melanoma skin cancer. * Without bilateral mastectomy or prophylactic mastectomy of the contralateral breast following diagnosis of their first primary. Matching of Controls: Controls eligible for inclusion in this study will be individually matched (1:1) to cases on: * Enrollment site (cancer registry); * Age at diagnosis of the cases first primary(within 5-year age groups); * Year of diagnosis of the cases first primary;(within 4-year categories); * Race/ethnicity (white, black, Latina, Asian, other). Exclusion Criteria: Exclusion for Cases: Women with any of the following characteristics will be ineligible as a case: * Unable to speak English in U.S. or Canadian enrolling sites or Spanish in the California site, and Danish in Denmark * Unable to sign informed consent * Stage IV distant metastases for either the first or second primary (lymph node metastasis is acceptable, but there should be no organ involvement * Simultaneous diagnosis of invasive in one breast and in situ in the other breast Exclusion for Controls: Women with any of the following characteristics will be ineligible as a control: * Unable to speak English in U.S. and Canadian enrolling sites, or Spanish in the California site and Danish in Demark * Unable to sign informed consent * Stage IV distant metastases (lymph node metastasis is acceptable, but there should be no organ involvement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bilateral breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Danish Cancer Society

    Copenhagen, Denmark

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • ONTARIO CANCER REGISTRY, Mount Sinai Hospital, Toronto

    Toronto, Ontario, M5G 1X5, Canada

  • Stanford University

    Stanford, California, 94305, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.